



## Nifedipine

**Catalog No: tcsc2296** 

| Availab   | ole Sizes                     |   |  |
|---|-------------------------------|---|--|
| Size: 1g  |                               |   |  |
| Size: 5g  |                               |   |  |
| Size: 10g   |                               |   |  |
| Specific  | cations                       |   |  |
| <b>CAS No:</b> 21829-25-4                               |                               |   |  |
| <b>Formula:</b> $C_{17}^{H}{}_{18}^{N}{}_{2}^{O}{}_{6}$ |                               |   |  |
| <b>Pathway:</b><br>Membrane Tran                        | sporter/lon Channel;Autophagy | , |  |
| <b>Target:</b><br>Calcium Channe                        | el;Autophagy                  |   |  |
| Purity / Grade<br>>98%                                  | <b>:</b>                      |   |  |
| <b>Solubility:</b><br>DMSO : ≥ 116.7                    | ' mg/mL (336.96 mM)           |   |  |
| <b>Alternative Na</b><br>BAY-a-1040                     | ames:                         |   |  |
| Observed Mole   | ecular Weight:                |   |  |

## **Product Description**



Nifedipine is a potent calcium channel blocker and drug of choice for cardiac insufficiencies.

In Vitro: Nifedipine (100 μM) significantly lowers the viability of the WKPT-0293 Cl.2 Cells, and treatment of nifedipine (10 or 100 μM) plus FAC induces a significant reduction in cell viability, but there are no significant differences in viability between the control cells and the cells treated with 100 μM of FAC or 1 and 10 μM of nifedipine. Nifedipine (1, 10, or 100 μM) significantly increases iron level in WKPT-0293 Cl.2 cells. Nifedipine treatment also increases expression of TfR1, DMT1+IRE and DMT1-IRE in WKPT-0293 Cl.2 cells. In addition, co-treatment with nifedipine (100 μM) and FAC (100 μM) increases TfR1, DMT1+IRE and DMT1-IRE expression in WKPT-0293 Cl.2 cells<sup>[2]</sup>. Nifedipine plus ritodrine produces a significantly greater inhibition of contractility than each drug alone in the midrange of concentrations. The combination of nifedipine plus nitroglycerin or nifedipine plus atosiban produces a significantly greater inhibition than nitroglycerin or atosiban alone but not greater than nifedipine. The combination of nifedipine plus NS-1619 (Ca  $^{2+}$ -activated K<sup>+</sup> [BKCa] channel opener) reduces the inhibitory effect of each drug<sup>[3]</sup>. Nifedipine (2 μM) significantly inhibits *P. capsici* mycelial growth and sporulation. Nifedipine-induced inhibition of mycelial growth is calcium-dependent. Nifedipine (0.5 μM) increases *P. capsici* sensitivity to H  $^{2}$ O<sub>2</sub> in a calcium-dependent manner. Nifedipine inhibition of *P. capsici* virulence and expression of genes involved in pathogenicity<sup>[4]</sup>.

*In Vivo:* In Nifedipine (50 mg/kg)- and CsA-treated rats, the BL dimensions (BLi and BLk), MD dimensions (MDk) and vertical dimensions (VHi and VHk) are significantly increased (P [1].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!